These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 22134793)

  • 21. Development and reliability of a multi-modality scoring system for evaluation of disease progression in pre-clinical models of osteoarthritis: celecoxib may possess disease-modifying properties.
    Panahifar A; Jaremko JL; Tessier AG; Lambert RG; Maksymowych WP; Fallone BG; Doschak MR
    Osteoarthritis Cartilage; 2014 Oct; 22(10):1639-50. PubMed ID: 25278073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Celecoxib does not affect the release of hyaluronic acid in end stage osteoarthritic joints.
    Takahashi D; Majima T; Onodera T; Kasahara Y; Inoue M; Irie T; Kasemura T
    Mod Rheumatol; 2013 Sep; 23(5):934-8. PubMed ID: 23001685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
    Sakamoto C; Soen S
    Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment.
    de Boer TN; Huisman AM; Polak AA; Niehoff AG; van Rinsum AC; Saris D; Bijlsma JW; Lafeber FJ; Mastbergen SC
    Osteoarthritis Cartilage; 2009 Apr; 17(4):482-8. PubMed ID: 18926729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial.
    Detrembleur C; De Nayer J; van den Hecke A
    Osteoarthritis Cartilage; 2005 Mar; 13(3):206-10. PubMed ID: 15727886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pain management in patients with osteoarthritis.
    Finucane TE
    JAMA; 2003 Jul; 290(1):36; author reply 36. PubMed ID: 12837705
    [No Abstract]   [Full Text] [Related]  

  • 30. Glucosamine & chondroitin use questioned in mild cases. Drug combo benefits moderate-to-severe knee osteoarthritis, but not so with lesser cases.
    Health News; 2006 Mar; 12(3):5-6. PubMed ID: 16535766
    [No Abstract]   [Full Text] [Related]  

  • 31. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial.
    Dentali F; Douketis JD; Woods K; Thabane L; Foster G; Holbrook A; Crowther M
    Ann Pharmacother; 2006; 40(7-8):1241-7. PubMed ID: 16804099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis.
    Zeng C; Wei J; Li H; Yang T; Gao SG; Li YS; Xiong YL; Xiao WF; Luo W; Yang TB; Lei GH
    Sci Rep; 2015 May; 5():10593. PubMed ID: 26012738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis.
    Ozgocmen S; Ardicoglu O; Erdogan H; Fadillioglu E; Gudul H
    Ann Clin Lab Sci; 2005; 35(2):137-43. PubMed ID: 15943176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing.
    Stengaard-Pedersen K; Ekesbo R; Karvonen AL; Lyster M
    Rheumatology (Oxford); 2004 May; 43(5):592-5. PubMed ID: 14762227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
    Cryer BL; Sostek MB; Fort JG; Svensson O; Hwang C; Hochberg MC
    Ann Med; 2011 Dec; 43(8):594-605. PubMed ID: 22017620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial.
    Rother M; Lavins BJ; Kneer W; Lehnhardt K; Seidel EJ; Mazgareanu S
    Ann Rheum Dis; 2007 Sep; 66(9):1178-83. PubMed ID: 17363401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COX-2 inhibitor.
    Gøtzsche PC; Bjarnason NH
    Rheumatology (Oxford); 2007 Oct; 46(10):1623-4; author reply 1624-5. PubMed ID: 17726033
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network meta-analysis.
    Zhu X; Wu D; Sang L; Wang Y; Shen Y; Zhuang X; Chu M; Jiang L
    Clin Exp Rheumatol; 2018; 36(4):595-602. PubMed ID: 29465368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
    Mateos JL
    Drugs Today (Barc); 2010 Feb; 46 Suppl A():1-25. PubMed ID: 20224826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
    Gómez de la Fuente E; Pampín Franco A; Caro Gutiérrez D; López Estebaranz JL
    Actas Dermosifiliogr; 2014 Apr; 105(3):314-5. PubMed ID: 24661957
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.